Literature DB >> 20535791

Avoiding common pitfalls in the analysis of observational studies of new treatments for rheumatoid arthritis.

Marie Hudson1, Samy Suissa.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20535791     DOI: 10.1002/acr.20124

Source DB:  PubMed          Journal:  Arthritis Care Res (Hoboken)        ISSN: 2151-464X            Impact factor:   4.794


× No keyword cloud information.
  11 in total

1.  Validation of administrative case ascertainment algorithms for chronic childhood arthritis in Manitoba, Canada.

Authors:  Natalie Jane Shiff; Kiem Oen; Rasheda Rabbani; Lisa M Lix
Journal:  Rheumatol Int       Date:  2017-05-13       Impact factor: 2.631

2.  Initiation of tumor necrosis factor-α antagonists and the risk of hospitalization for infection in patients with autoimmune diseases.

Authors:  Carlos G Grijalva; Lang Chen; Elizabeth Delzell; John W Baddley; Timothy Beukelman; Kevin L Winthrop; Marie R Griffin; Lisa J Herrinton; Liyan Liu; Rita Ouellet-Hellstrom; Nivedita M Patkar; Daniel H Solomon; James D Lewis; Fenglong Xie; Kenneth G Saag; Jeffrey R Curtis
Journal:  JAMA       Date:  2011-11-06       Impact factor: 56.272

3.  Perioperative use of anti-rheumatic agents does not increase early postoperative infection risks: a Veteran Affairs' administrative database study.

Authors:  Zaki Abou Zahr; Andrew Spiegelman; Maria Cantu; Bernard Ng
Journal:  Rheumatol Int       Date:  2014-09-04       Impact factor: 2.631

4.  Dynamic patterns and predictors of hydroxychloroquine nonadherence among Medicaid beneficiaries with systemic lupus erythematosus.

Authors:  Candace H Feldman; Jamie Collins; Zhi Zhang; S V Subramanian; Daniel H Solomon; Ichiro Kawachi; Karen H Costenbader
Journal:  Semin Arthritis Rheum       Date:  2018-01-08       Impact factor: 5.532

5.  Factors associated with methotrexate dosing and therapeutic decisions in veterans with rheumatoid arthritis.

Authors:  Bernard Ng; Adeline Chu
Journal:  Clin Rheumatol       Date:  2013-08-11       Impact factor: 2.980

6.  An observational study of tocilizumab and TNF-α inhibitor use in a Japanese community hospital: different remission rates, similar drug survival and safety.

Authors:  Kazuki Yoshida; Yasuharu Tokuda; Hideto Oshikawa; Masako Utsunomiya; Tatsuo Kobayashi; Makiko Kimura; Gautam A Deshpande; Kazuo Matsui; Mitsumasa Kishimoto
Journal:  Rheumatology (Oxford)       Date:  2011-09-02       Impact factor: 7.580

7.  Effect of menopause on the modified Rodnan skin score in systemic sclerosis.

Authors:  Évelyne Vinet; Sasha Bernatsky; Marie Hudson; Christian A Pineau; Murray Baron
Journal:  Arthritis Res Ther       Date:  2014-06-23       Impact factor: 5.156

8.  Treatment of Rheumatoid Arthritis With Anti-Tumor Necrosis Factor or Tocilizumab Therapy as First Biologic Agent in a Global Comparative Observational Study.

Authors:  Ernest H Choy; Corrado Bernasconi; Maher Aassi; Jose Fernando Molina; Oscar Massimiliano Epis
Journal:  Arthritis Care Res (Hoboken)       Date:  2017-09-06       Impact factor: 4.794

9.  Establishment of a framework for assessing mortality in persons with congenital hemophilia A and its application to an adverse event reporting database.

Authors:  Steven W Pipe; Rebecca Kruse-Jarres; Johnny N Mahlangu; Glenn F Pierce; Flora Peyvandi; Peter Kuebler; Christian De Ford; Fabián Sanabria; Richard H Ko; Tiffany Chang; Charles R M Hay
Journal:  J Thromb Haemost       Date:  2021-01       Impact factor: 5.824

10.  A retrospective cohort study: 10-year trend of disease-modifying antirheumatic drugs and biological agents use in patients with rheumatoid arthritis at Veteran Affairs Medical Centers.

Authors:  Bernard Ng; Adeline Chu; Myrna M Khan
Journal:  BMJ Open       Date:  2013-04-05       Impact factor: 2.692

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.